Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis

Tvardi Therapeutics, Inc. announced that its lead product, TTI-101, has been granted Orphan Drug Designation by the US FDA for the treatment of idiopathic pulmonary fibrosis.